Catalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for ACTengine® IMA203 GEN1 (PRAME) in Cutaneous melanoma. The expected timing is based on the latest available company guidance and may change.
SUPRAME trial. Trial-in-progress poster at ASCO '25. 5/31/25- To complete enrollment in 2026. Submit BLA in Q1 2027. 11/17/25:- SUPRAME Ph3 ongoing; interim/final analyses expected in 2026; BLA submission planned H1 2027. 03/05/26:- ODD and RMAT granted for cutaneous and uveal melanoma; SUPRAME Ph3 analyses 2026; BLA H1 2027; launch H2 2027. 05/12/26:- SUPRAME Ph3 interim and final PFS analyses expected in 2026; BLA H1 2027; first commercial launch H2 2027. 08/18/26:- SUPRAME final PFS topline data is expected in H1 2027. BLA submission will follow in 2027.
Verification
Confirm timing and program details against the company announcement or filing.